GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Cash Payments for Deposits by Banks and Customers

ACADIA Pharmaceuticals (FRA:DR6) Cash Payments for Deposits by Banks and Customers


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Cash Payments for Deposits by Banks and Customers?

Cash Payments for Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


ACADIA Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Cash Payments for Deposits by Banks and Customers
Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.